<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801787</url>
  </required_header>
  <id_info>
    <org_study_id>EA4/123/12</org_study_id>
    <nct_id>NCT01801787</nct_id>
  </id_info>
  <brief_title>Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia</brief_title>
  <official_title>The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study investigates the basic principles that underlie the efficacy of
      transcranial direct current stimulation for chronic auditory verbal hallucinations in
      schizophrenia in a multimodal design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of Auditory Hallucination Rating Scale score</measure>
    <time_frame>baseline; 3 days after intervention; 3 months after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Auditory Hallucination Rating Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are primary outcome measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive And Negative Syndrome Scale</measure>
    <time_frame>baseline; 3 days after intervention; 3 months after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive And Negative Syndrome Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are secondary outcome measures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>N1 suppression during talking and listening</measure>
    <time_frame>baseline; 3 days after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>N1 suppression during talking and listening will be assessed at baseline; change thereof at 3 days after intervention is further outcome measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Diffusion Tensor Imaging: Fractional anisotropy of longitudinal superior fascicle and arcuate fascicle</measure>
    <time_frame>baseline; 3 days after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fractional anisotropy of longitudinal superior fascicle and arcuate fascicle will be assessed at baseline; change thereof 3 days after intervention is further outcome measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Default Mode Network connectivity</measure>
    <time_frame>baseline; 3 days after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Default Mode Network connectivity will be assessed at baseline; change thereof 3 days after intervention is further outcome measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Auditory Verbal Hallucinations</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>verum tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>active vs. sham tDCS left hemisphere</description>
    <arm_group_label>verum tDCS</arm_group_label>
    <arm_group_label>sham tDCS</arm_group_label>
    <other_name>device: neuroConn tDCS PLUS device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of schizophrenia

          -  chronic auditory verbal hallucinations

          -  right-handed

        Exclusion Criteria:

          -  drug abuse other than nicotine

          -  severe cognitive deficits

          -  severe medical conditions

          -  severe neurological disorders

          -  severe microangiopathy

          -  history of electroconvulsive therapy

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lindenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Charité University Medicine Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres H. Neuhaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Charité University Medicine Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andres H. Neuhaus, MD</last_name>
    <phone>00493084458412</phone>
    <email>andres.neuhaus@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité University Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres H. Neuhaus, MD</last_name>
      <phone>00493084458412</phone>
      <email>andres.neuhaus@charite.de</email>
    </contact>
    <investigator>
      <last_name>Andres H. Neuhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lindenberg, MD</last_name>
      <phone>0049450560365</phone>
      <email>robert.lindenberg@charite.de</email>
    </contact>
    <investigator>
      <last_name>Robert Lindenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 22, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andres Neuhaus</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
